Pharmaceutical

Sermonix and Regor to enhance breast cancer treatment options

Sermonix Pharmaceuticals and Regor have announced a strategic partnership aimed at developing therapeutics in the breast oncology area.

Mar 25, 2025 - 06:00
Sermonix and Regor to enhance breast cancer treatment options
Sermonix Pharmaceuticals and Regor have announced a strategic partnership aimed at developing therapeutics in the breast oncology area.
Read the original article

Tags:

Previous Article

Ferroptosis Plays a Key Role in Immunosuppression

Next Article

Tempero secures $70m to advance addiction treatment candidate

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more

STAT+: Pharmalittle: We’re reading about weight loss dr...

Feb 21, 2024

FDA grants breakthrough therapy status for Nuvalent’s NVL-655

FDA grants breakthrough therapy status for Nuvalent’s N...

May 19, 2024

Fosigotifator by Calico Life Sciences for Unspecified C...

Jan 6, 2025